Symposium
Thu. May 20, 2021 8:00 AM - 9:30 AM Room 04 (ICC Kyoto 2F Room A)
Chair：Igarashi Hisaka(Headache Care Unit, Department of Internal Medicine, Fujitsu Clinic),Takahashi Makio(Department of Neurology, Osaka Red Cross Hospital)
後援：日本頭痛学会
Migraine is a common disabling primary headache disorder that is highly prevalent and imposes a significant burden on patients, society, and the healthcare system, in many parts of the world. The anti-CGRP receptor monoclonal antibody (erenumab) and anti-CGRP monoclonal antibodies such as fremanezumab, galcanezumab and epitinezumab are newer drugs approved by the FDA in 2018 for prophylactic treatment of migraine.
The 5-HT1F receptor agonist (Lasmiditan) and oral calcitonin gene-related peptide (CGRP) receptor antagonists (ubrogepant) are also approved for acute treatment of migraine by the FDA. Some of these new drugs will be available in Japan in 2021. Neurologists should know how the emergence of these drugs has changed migraine management in the real world and it is important to know whether patients are satisfied with those treatments.
○Toshihiko Shimizu (Department of Neurology, Keio University, Japan)
Schedule
Like
)
○Patricia Pozo-Rosich (Headache Unit & Research Group, Vall Hebron University Hospital & Vall Hebron Insitute of Research (VHIR), Spain)
Schedule
Like
)
○Yoshiko Unno (Department of Stroke and Cerebrovascular Medicine, Faculty of Medicine, Kyorin University, Japan)
Schedule
Like
)
○Noboru Imai (Department of Neurology, Japanese Red Cross Shizuoka Hospital, Japan)
Schedule
Like
)